Avidity Biosciences Inc (RNA) Financial Health: Profitability & Balance Sheet Analysis
Avidity Biosciences Inc (RNA) shows robust financial health with a score of 9.39, ranking highly within the Pharmaceuticals industry. The company reported significant growth, with its latest quarterly revenue increasing by 1148.25% year-over-year and net profit rising by 85.63%. Its operating efficiency is noted as high, although detailed financial data for various metrics like cash flow and total assets has not yet been disclosed.
Avidity Biosciences Stock - Long-term strategy around RNA therapeutics
This article focuses on Avidity Biosciences' long-term strategy, clinical pipeline, and funding status as a pre-commercial biotechnology company. The company specializes in developing RNA-based therapies for rare muscle and neuromuscular diseases using antibody-oligonucleotide conjugates (AOCs). Key programs target myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy, with a goal to expand into broader disease areas.
Avidity Biosciences Inc (RNA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Avidity Biosciences Inc (RNA), highlighting its current earnings forecast score of 8.00 and an average price target of $72.00, with an upside of 96.08%. Based on analytics from 2 analysts, the stock receives a "Strong Buy" rating. The report also details expected revenue for the next quarter and past EPS performance.
Avidity Biosciences Inc (RNA) Valuation: PE, PB & Fair Value Analysis
Avidity Biosciences Inc (RNA) has a valuation score of 8.73, placing it 70th out of 157 companies in the Pharmaceuticals industry. The company's current P/E ratio is -4.38, showing a significant change from its recent high and low. Relevant data for P/B, P/S, and P/CF ratios are not yet disclosed by the company.
Avidity Biosciences Inc (RNA) Institutional Confidence
Avidity Biosciences Inc (RNA) has an institutional shareholding score of 3.00, placing it 94th out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 29.04%, marking a significant quarter-over-quarter decrease of 70.62%. Paul Tudor Jones is the largest institutional shareholder, holding 0.42% of outstanding shares with a 0.67% increase in his holdings.
Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its business segments, regional revenue, and profit contribution. It shows that the company's revenue from the United States was $18.62 million, with segment and regional data not yet fully disclosed. The article highlights the current stock price and market capitalization, providing a snapshot of the company's financial overview.
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
Novartis announced that del-brax, an RNA drug acquired in its $12 billion deal with Avidity Biosciences, met its primary biomarker endpoint in a Phase 1/2 study for facioscapulohumeral muscular dystrophy (FSHD). The drug, delpacibart braxlosiran, is designed to restore muscle function by targeting the DUX4 gene, which is expressed incorrectly in FSHD patients. This positive trial data partially validates Novartis's acquisition and paves the way for a Phase 3 trial and potential accelerated approval, with investors also anticipating results from two other AOC drugs in development.
Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners
Leerink Partners has set a price target of $25.00 per share for Avidity Biosciences (NASDAQ: RNA). This new target suggests a potential for significant movement in the company's stock, according to the analyst firm. Investors will likely be watching how Avidity Biosciences reacts to this updated valuation.
Avidity Biosciences (RNAM) Schedule 13G/A: RA Capital, Kolchinsky, Shah update ownership
Avidity Biosciences (RNAM) has filed a Schedule 13G/A, an amendment by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah. This filing updates their beneficial ownership, indicating positions equal to or below 5% of the class as of March 31, 2026. The reporting persons collectively disclaim status as a "group," emphasizing that their disclosures are individual rather than collaborative for control purposes.
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth between 2020 and 2034, driven by increasing prevalence and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, Avidity Biosciences, and Fulcrum Therapeutics are developing late-stage therapies, including gene-targeting treatments and Antibody Oligonucleotide Conjugates (AOCs™). The market is seeing considerable advancements in clinical trials, with several candidates showing promise in reducing DUX4 gene expression and improving patient outcomes, with a large unmet need for treatments.
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion - DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is poised for rapid expansion, driven by an increasing prevalence of the disease and a robust pharmaceutical pipeline. Key companies like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics are developing therapies such as DYNE-301, MC-DX4, and Losmapimod, with several candidates showing promising clinical results, including Sarepta Therapeutics' siRNA programs and Avidity Biosciences' delpacibart braxlosiran. The market's growth is further supported by governmental efforts to facilitate research and a high likelihood of reimbursement for upcoming therapies, given the current lack of approved treatments for FSHD.
Who is the CEO of Avidity Biosciences in 2026? Sarah Boyce's Bio
Sarah Boyce is the President and CEO of Avidity Biosciences, a role she has held since October 2019. With over 25 years of leadership experience in the pharmaceutical and biopharmaceutical industries, she has been crucial in transforming Avidity from a research-focused company into a clinical-stage firm. Her leadership has guided the company through significant milestones, including funding rounds and an IPO, while advancing multiple RNA therapies into clinical development.
Linklaters advises on USD 11.0 bn financing by Novartis of the acquisition of Avidity Biosciences
Linklaters advised a global underwriting syndicate on an USD 11 billion SEC-registered bond issuance by Novartis. The proceeds will be used for general corporate purposes and to repay a bridge loan that financed Novartis' USD 12 billion acquisition of Avidity Biosciences. The international Linklaters team was led by Marco Carbonare, Kevin Roy, and Danelle Le Cren.
Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial
CAMP4 Therapeutics (Nasdaq: CAMP) has appointed Michael MacLean, a veteran biotech CFO with over 35 years of experience, to its Board of Directors. This strategic move coincides with the company advancing its CMP-002 program for SYNGAP1-related disorder towards a planned first-in-human Phase 1/2 clinical trial. MacLean's extensive background includes leadership roles at Avidity Biosciences, Akcea Therapeutics, PureTech Health, and Biogen, bringing valuable financial and operational expertise to CAMP4 during this critical growth phase.
Novartis Completes $12-Bn Acquisition of Avidity Biosciences
Novartis has finalized its $12 billion acquisition of Avidity Biosciences to enhance its late-stage neuroscience pipeline. Avidity specializes in RNA therapeutics and antibody oligonucleotide conjugates (AOCs) for rare genetic neuromuscular diseases. This acquisition provides Novartis with Avidity’s AOC platform and three key late-stage programs targeting Myotonic Dystrophy Type 1, Facioscapulohumeral Muscular Dystrophy, and Duchenne Muscular Dystrophy.
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to develop treatments that target the underlying cause of these severe heart conditions. Atrium plans to file INDs for its lead assets in late 2026 and 2027, with the potential to expand its reach beyond rare diseases to broader cardiomyopathy patient populations.
[15-12G] Avidity Biosciences, Inc. SEC Filing
This article announces an SEC filing by Avidity Biosciences, Inc. (RNAM) of Form 15, which is a certification and notice of termination of registration under Section 12(g) or suspension of duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing was signed by Jaime Huertas, Secretary, on March 9, 2026. The company is headquartered in San Diego, California, and has common stock with a par value of $0.0001 per share.
Novartis, Avidity Deal Spins Out New RNA Co.
Atrium Therapeutics, a new RNA company, launched in February with $270 million in funding as a spinoff following Novartis' $12 billion acquisition of Avidity Biosciences. Atrium will focus on developing RNA therapeutics for rare muscle diseases, particularly in the precision cardiology space, leveraging Avidity's antibody-oligonucleotide conjugate (AOC) platform. The company plans to submit Investigational New Drug applications for two lead candidates, ATR 1072 and ATR 1086, later this year and in 2027, respectively, and retained Avidity's former CEO, Sarah Boyce, as chair of its board.
RNAM SEC Filings - Avidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Avidity Biosciences's (Ticker: RNAM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores from Rhea-AI, and end-of-day stock performance data to offer insights into market reactions. The resource is designed for investors and regulatory compliance professionals to navigate critical disclosures and financial reporting.
Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis
This article reports that Avidity Biosciences (RNA) saw its stock price reach an all-time high due to rumors of a potential $12-billion merger with Novartis. This speculative news has significantly boosted investor confidence in RNA.
Avidity Biosciences Inc (RNAM) Fundamental Analysis
This article provides a fundamental analysis of Avidity Biosciences Inc (RNAM), highlighting its weak financial fundamentals. Key concerns include a negative PE ratio, profit margin, and ROE, alongside weak or negative revenue and EPS growth. Despite these weaknesses, the company shows strengths in its cash position, PEG ratio, and current ratio, and is noted as potentially undervalued based on its PE and PEG ratios.
Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies
Atrium Therapeutics has launched as an independent publicly traded company, spun off from Novartis' acquisition of Avidity Biosciences. The new company aims to develop RNA therapies for rare and life-threatening genetic cardiomyopathies, leveraging approximately $270 million in cash equivalents. Atrium's lead candidates, ATR 1072 and ATR 1086, are designed to address PRKAG2 syndrome and PLN cardiomyopathy, with IND filings anticipated in 2026 and 2027, respectively.
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Hold" from Analysts
Avidity Biosciences, Inc. (NASDAQ:RNA) has received an average "Hold" rating from twenty-one analysts, with an average 12-month price target of $69.57. Recent insider selling of 58,407 shares worth $4.23 million was noted, alongside a Q3 earnings miss where EPS of ($1.59) and revenue of $0.86 million fell short of expectations. The company, focused on developing antibody-oligonucleotide conjugate therapies, shows deeply negative margins and return on equity.
Avidity Biosciences, Inc.(NasdaqGM: RNAM) dropped from S&P TMI Index
Avidity Biosciences, Inc. (NasdaqGM: RNAM) has been removed from the S&P TMI Index, as announced on March 2, 2026. This follows several other recent removals from various S&P and Russell indices, including the S&P Global BMI Index, S&P Biotechnology Select Industry Index, and multiple Russell Growth and Value benchmarks, all noted around March 1-2, 2026. Avidity Biosciences is a biopharmaceutical company focused on developing antibody oligonucleotide conjugates (AOCs) for RNA therapeutics.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data for their del-zota treatment for DMD44, patient experiences with del-desiran for DM1, and other research on muscular dystrophies. Avidity will also host an industry forum lunch event focused on biomarker advancements in rare neuromuscular diseases.
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM
This article focuses on the operating expenses (excluding COGS) of Avidity Biosciences, Inc., traded on NASDAQ under the symbol RNAM. It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors and analysts. The content itself is minimalist, primarily serving as a header for more detailed financial information presumably available on the platform.
Avidity Biosciences, Inc. (RNAM) Leadership & Management Team Analysis
This article provides an in-depth analysis of Avidity Biosciences, Inc.'s leadership and management team, highlighting key figures like CEO Sarah Boyce, her compensation, and tenure. It also details the experience of the broader management team and board of directors, alongside recent company updates and changes in executive roles and stock transactions. Financial data related to CEO compensation relative to company earnings is presented.
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger
Avidity Biosciences' Chief Legal Officer, John B. Moriarty, reported the disposition of company equity, including 92,054 shares of Common Stock and stock options for 50,000 and 160,000 shares, due to a merger with Novartis AG. The Common Stock and underlying restricted stock units, as well as the stock options, were exchanged for cash based on the merger consideration of $72.00 per share. This transaction resulted in Moriarty holding no shares for the affected positions after the merger.
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Atrium Therapeutics, a new spinout from Avidity Biosciences, launched with $270 million to develop RNA medicines for rare heart conditions, four months after Novartis acquired Avidity for $12 billion. Led by Avidity's former Chief Program Officer Kathleen Gallagher and chaired by its ex-CEO Sarah Boyce, Atrium will focus on areas like PRKAG2 syndrome and PLN cardiomyopathy, which were not part of the Novartis acquisition. The company leverages Avidity's pioneering work in targeted RNA delivery, specifically its methods for sending RNA medicines into muscle tissue.
Avidity Biosciences Announced Transfer or Voluntary Withdrawal of Listing
Avidity Biosciences (RNAM) announced its intent to delist from Nasdaq following a consummated merger. Trading of the company's common stock will be suspended on March 2, 2026, and a Form 15 will be filed to terminate registration and suspend reporting obligations after the Form 25 for delisting becomes effective. This information is based on an SEC filing from February 27, 2026.
Avidity Biosciences (Nasdaq:RNAM) - Stock Analysis
Avidity Biosciences (Nasdaq:RNAM) is a biopharmaceutical company engaged in developing RNA therapeutics. The company is currently unprofitable but is forecast to grow revenue by 51.74% per year, trading considerably below Simply Wall St's fair value estimate. Recent updates include final results from a Phase 1/2 trial for Myotonic Dystrophy Type 1 and an agreement for Novartis to acquire the company for $10.6 billion.
S&P 500 Futures Decline in Premarket Trading; Avidity Biosciences, Duolingo Lag
The Dow Jones Industrial Average fell sharply on Friday, dropping 522 points, but still managed to secure its tenth consecutive monthly gain. The S&P 500 and Nasdaq Composite also declined, on both the day and the month. Factors contributing to the market downturn included concerns about private-credit following a bank selloff, Block's workforce reduction announcement, and anxieties surrounding AI's impact on employment.
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Atrium Therapeutics, a new biotech spinout from Novartis' acquisition of Avidity Biosciences, has officially debuted with $270 million in cash. Led by Kathleen Gallagher, the company will focus on advancing two preclinical small interfering RNA candidates, ATR 1072 and ATR 1086, for rare genetic heart conditions, with planned Phase 1 trials in late 2026 and 2027 respectively. Atrium inherited Avidity's stock market presence and aims to develop precision medicines for cardiac diseases.
Avidity Biosciences, Inc. $RNA Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly increased its stake in Avidity Biosciences, purchasing over 300,000 additional shares to own 0.62% of the company, valued at approximately $39.2 million. This comes despite Avidity missing quarterly earnings estimates and experiencing notable insider share sales from its CEO and CFO. Analysts currently hold a consensus "Hold" rating on the stock with an average target price of $69.57.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida, from March 8-11, 2026. The presentations will cover data from its EXPLORE44 program for Duchenne muscular dystrophy (DMD44), patient journeys and treatment experiences in myotonic dystrophy type 1 (DM1), and research in facioscapulohumeral muscular dystrophy (FSHD). Avidity will also host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
Avidity Biosciences announced the expansion of its RNA therapeutic discovery pipeline, adding new research and development candidates in skeletal muscle and cardiology. The company is leveraging its proprietary AOC platform to target previously untreatable diseases and continues to advance three rare disease programs in Phase 1/2 clinical development for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Avidity also maintains collaborations with Eli Lilly and Company and MyoKardia to further explore its AOC platform's potential.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Avidity Biosciences (Nasdaq: RNA) announced it will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data from their EXPLORE44 program for Duchenne muscular dystrophy (DMD44) and insights into myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida. The presentations will cover data from their EXPLORE44 program for Duchenne muscular dystrophy, patient journeys and treatment experiences in Myotonic Dystrophy Type 1, and research on Facioscapulohumeral Muscular Dystrophy. Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.
One-year Duchenne study ties treatment to near-normal creatine kinase levels
Avidity Biosciences (NASDAQ: RNA) is set to present one oral and six poster presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in March. Key presentations will include 1-year data from their Phase 1/2 EXPLORE44 del-zota study for Duchenne muscular dystrophy (DMD44), which shows near normalization of creatine kinase levels and functional improvements. The company's upcoming presence at the conference highlights its continued focus on advancing RNA therapeutics for neuromuscular diseases.
A Look At Avidity Biosciences (RNA) Valuation After Strong Multi Year Shareholder Returns
Avidity Biosciences (RNA) has shown strong shareholder returns over the past three years, despite reporting significant net losses and modest revenue, indicating it's still in a development phase. The company's Price-to-Book ratio suggests it's valued similarly to high-growth peers, but a Discounted Cash Flow model indicates a substantial undervaluation compared to its current price. Investors are advised to consider the company's risks and growth potential carefully given the mixed signals in its valuation.
Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives
Avidity Biosciences (RNA) reported a net loss of US$237.1 million for FY 2025, bringing its trailing 12-month net loss to US$684.6 million against total revenue of US$18.8 million. While analysts forecast 51.4% annual revenue growth, challenging the current loss-making trend, critics point to expanding losses and a P/B ratio higher than the industry average. Despite a significant DCF fair value indicating undervaluation, the company faces skepticism regarding its path to profitability and shareholder dilution.
Rhumbline Advisers Decreases Stake in Avidity Biosciences, Inc. $RNA
Rhumbline Advisers reduced its stake in Avidity Biosciences (NASDAQ:RNA) by 9.9% in Q3, selling 17,288 shares and ending the quarter with 158,071 shares valued at approximately $6.887 million. While Rhumbline decreased its holdings, other institutions like Norges Bank and Bank of America significantly increased their positions. Insiders, however, have been net sellers, disposing of 58,407 shares in the last three months, though they still own 3.83% of the company.
Avidity Biosciences, Inc. SEC 10-K Report
Avidity Biosciences, Inc. has released its Form 10-K report for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and strategic initiatives. The report highlights the company's focus on developing Antibody Oligonucleotide Conjugates (AOCs) for rare diseases, significant R&D expenses, and a planned merger with Novartis AG. Challenges include merger uncertainty, ongoing operating losses, and risks associated with manufacturing and market conditions.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced it will adjourn its Special Meeting of Stockholders on February 23, 2026, and reconvene it on February 26, 2026. This adjournment is to allow more time to fulfill conditions for the pro rata distribution of Atrium Therapeutics, Inc. common stock to Avidity stockholders, which is a prerequisite for its proposed merger with Novartis AG. The distribution is expected on February 26, 2026, and the merger closing on February 27, 2026, with Avidity's common stock temporarily trading as "RNAM" during the distribution.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced its plan to adjourn its special stockholders meeting scheduled for February 23, 2026, and reconvene it on February 26, 2026. This adjournment is intended to allow more time to satisfy conditions for the pro rata distribution of Atrium Therapeutics shares, which is a precursor to Avidity's proposed merger with Novartis AG. The Distribution is now expected on February 26, 2026, with the merger closing on February 27, 2026, both subject to closing conditions including stockholder approval.
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring Growth Potential Amidst 434% Revenue Surge
Avidity Biosciences, Inc. (RNA) is a biopharmaceutical company demonstrating significant growth, with a 434% revenue surge and an $11.26 billion market capitalization. The company is advancing several RNA therapeutic programs through clinical trials for diseases like myotonic dystrophy type 1 and muscular dystrophies. Despite substantial investment in its pipeline leading to negative EPS and free cash flow, analyst sentiment indicates cautious optimism for its long-term potential in biotechnology.
Avidity Biosciences to adjourn Feb 23 special meeting; Distribution expected Feb 26, Merger close Feb 27
Avidity Biosciences will adjourn its special meeting scheduled for February 23rd, 2026, and reconvene on February 26th, 2026. This adjournment is to allow more time for the completion of the SpinCo distribution. The company expects the distribution to occur on February 26th, 2026, with the merger with Novartis closing the following day, February 27th, 2026, pending closing conditions.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced its intention to adjourn and reconvene a special meeting of stockholders to allow more time to satisfy conditions for the pro rata distribution of Atrium Therapeutics stock. This distribution is a prerequisite for its proposed merger with Novartis AG. The distribution is now expected on February 26, 2026, and the merger closing on February 27, 2026.
Biotech delays key vote as Atrium stock distribution, Novartis merger approach
Avidity Biosciences (NASDAQ: RNA) has adjourned its special meeting from February 23, 2026, to February 26, 2026, to allow for additional time to fulfill conditions for the pro rata distribution of Atrium Therapeutics (SpinCo) shares. This distribution is a prerequisite for the closing of Avidity's previously announced merger with Novartis AG. The SpinCo distribution is now expected on February 26, 2026, with the Novartis merger closing anticipated on February 27, 2026.
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences announced its intention to adjourn its special meeting of stockholders initially scheduled for February 23, 2026, and reconvene it on February 26, 2026. This adjournment is to allow additional time to satisfy the conditions for the pro rata distribution of Atrium Therapeutics, Inc. common stock, which is a prerequisite for the proposed merger with Novartis AG. The Distribution is now expected on February 26, 2026, and the merger closing on February 27, 2026, subject to closing conditions and stockholder approval.
